Open AccessIncidence and Clinical Course of Thrombotic Thrombocytopenic Purpura Due to Ticlopidine Following Coronary Stenting
Author(s) -
Steven R. Steinhubl
Publication year - 1999
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.281.9.806
Subject(s) - medicine , ticlopidine , thrombotic thrombocytopenic purpura , percutaneous coronary intervention , surgery , incidence (geometry) , coronary stent , stent , clopidogrel , myocardial infarction , restenosis , platelet , physics , optics
Thrombotic thrombocytopenic purpura (TTP) is a rare and often fatal disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, mental status changes, and renal dysfunction. Ticlopidine hydrochloride is 1 of several drugs that have been associated with this disorder and is currently used routinely in the approximately 5 patients per year in the United States who undergo a percutaneous coronary intervention involving a stent.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom